Answer
Women of childbearing potential receiving tildrakizumab should use effective contraception during treatment and for at least 17 weeks after treatment.
Sources for this answer
- Ilumetri 100 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 7Document updated
Sources checked